Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 28.2
(7.22%)
TWD 28.2
(7.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 473.81 Million TWD | -36.29% |
| 2022 | 743.72 Million TWD | 14.2% |
| 2021 | 651.27 Million TWD | -17.16% |
| 2020 | 786.2 Million TWD | 176.83% |
| 2019 | 250.75 Million TWD | -26.38% |
| 2018 | 165.73 Million TWD | 53.08% |
| 2017 | 252.01 Million TWD | 17.56% |
| 2016 | 214.36 Million TWD | -52.08% |
| 2015 | 447.31 Million TWD | 201.38% |
| 2014 | 148.42 Million TWD | -29.08% |
| 2013 | 181.99 Million TWD | -26.82% |
| 2012 | 289.79 Million TWD | 7.58% |
| 2011 | 261.55 Million TWD | 0.36% |
| 2010 | 348.31 Million TWD | -32.26% |
| 2009 | 354.63 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 64.36 Million TWD | -13.14% |
| 2024 Q2 | 73.53 Million TWD | -16.27% |
| 2023 Q1 | 276.23 Million TWD | 119.12% |
| 2023 Q4 | 101.1 Million TWD | 55.02% |
| 2023 Q2 | 101.15 Million TWD | -63.38% |
| 2023 FY | - TWD | -36.29% |
| 2023 Q3 | 65.21 Million TWD | -35.52% |
| 2022 Q1 | 191.34 Million TWD | 39.31% |
| 2022 Q4 | 126.06 Million TWD | -32.63% |
| 2022 Q3 | 187.12 Million TWD | -21.77% |
| 2022 FY | - TWD | 14.2% |
| 2022 Q2 | 239.18 Million TWD | 25.0% |
| 2021 Q2 | 187.48 Million TWD | 24.62% |
| 2021 Q3 | 157.64 Million TWD | -15.92% |
| 2021 FY | - TWD | -17.16% |
| 2021 Q1 | 150.44 Million TWD | -5.78% |
| 2021 Q4 | 137.35 Million TWD | -12.87% |
| 2020 Q4 | 159.68 Million TWD | 118.17% |
| 2020 Q3 | 73.19 Million TWD | -84.86% |
| 2020 Q1 | 69.75 Million TWD | -10.53% |
| 2020 FY | - TWD | 176.83% |
| 2020 Q2 | 483.58 Million TWD | 593.29% |
| 2019 Q4 | 77.96 Million TWD | 20.32% |
| 2019 FY | - TWD | -26.38% |
| 2019 Q3 | 64.79 Million TWD | 18.63% |
| 2019 Q2 | 54.61 Million TWD | -36.95% |
| 2019 Q1 | 86.62 Million TWD | 156.04% |
| 2018 FY | - TWD | 53.08% |
| 2018 Q3 | 256 Million TWD | 365.9% |
| 2018 Q2 | 54.94 Million TWD | 33.99% |
| 2018 Q1 | 41 Million TWD | -59.23% |
| 2018 Q4 | 33.83 Million TWD | -86.78% |
| 2017 Q1 | 20.72 Million TWD | -69.51% |
| 2017 Q3 | 107.73 Million TWD | 368.85% |
| 2017 Q2 | 22.97 Million TWD | 10.88% |
| 2017 Q4 | 100.57 Million TWD | -6.65% |
| 2017 FY | - TWD | 17.56% |
| 2016 Q4 | 67.97 Million TWD | 42.46% |
| 2016 Q1 | 49.11 Million TWD | -57.8% |
| 2016 Q3 | 47.71 Million TWD | -3.72% |
| 2016 FY | - TWD | -52.08% |
| 2016 Q2 | 49.55 Million TWD | 0.89% |
| 2015 Q3 | 65.22 Million TWD | 52.18% |
| 2015 FY | - TWD | 201.38% |
| 2015 Q1 | 222.81 Million TWD | 311.0% |
| 2015 Q2 | 42.86 Million TWD | -80.76% |
| 2015 Q4 | 116.4 Million TWD | 78.46% |
| 2014 Q2 | 53.67 Million TWD | 33.23% |
| 2014 Q3 | 253 Thousand TWD | -99.53% |
| 2014 Q1 | 40.28 Million TWD | 42.37% |
| 2014 FY | - TWD | -29.08% |
| 2014 Q4 | 54.21 Million TWD | 21328.06% |
| 2013 Q1 | 72.31 Million TWD | 135.49% |
| 2013 FY | - TWD | -26.82% |
| 2013 Q3 | 34.24 Million TWD | -53.98% |
| 2013 Q4 | 28.29 Million TWD | -17.38% |
| 2013 Q2 | 74.41 Million TWD | 2.91% |
| 2012 Q2 | 122.66 Million TWD | 102.79% |
| 2012 FY | - TWD | 7.58% |
| 2012 Q4 | 30.7 Million TWD | -56.98% |
| 2012 Q3 | 71.38 Million TWD | -41.81% |
| 2012 Q1 | 60.49 Million TWD | -18.21% |
| 2011 Q2 | 48.55 Million TWD | -27.24% |
| 2011 Q1 | 66.72 Million TWD | 34.96% |
| 2011 Q3 | 72.32 Million TWD | 48.98% |
| 2011 FY | - TWD | 0.36% |
| 2011 Q4 | 73.95 Million TWD | 2.25% |
| 2010 Q1 | 56.34 Million TWD | 0.0% |
| 2010 FY | - TWD | -32.26% |
| 2010 Q2 | 78.68 Million TWD | 39.64% |
| 2010 Q4 | 49.44 Million TWD | -38.49% |
| 2010 Q3 | 80.38 Million TWD | 2.16% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Apex Biotechnology Corp. | 221.06 Million TWD | -114.337% |
| Sinphar Pharmaceutical Co.,Ltd. | 582.94 Million TWD | 18.72% |
| Panion & Bf Biotech Inc. | 327.21 Million TWD | -44.8% |
| GenMont Biotech Incorporation | 71.76 Million TWD | -560.202% |
| Abnova (Taiwan) Corporation | 81.2 Million TWD | -483.45% |
| Adimmune Corporation | -512.42 Million TWD | 192.465% |
| Tanvex BioPharma, Inc. | -1.75 Billion TWD | 127.006% |
| Polaris Group | -1.38 Billion TWD | 134.1% |
| Energenesis Biomedical CO.,LTD. | -244.57 Million TWD | 293.728% |
| UnicoCell Biomed Co., Ltd. | -56.27 Million TWD | 941.947% |
| PELL Bio-Med Technology Co. Ltd. | -353.17 Million TWD | 234.157% |